ClinicalTrials.gg
CompletedNCT02583594SCALAUpdated Mar 10, 2021

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

A Phase 1 interventional study of Acyclovir and Methylprednisolone in Progressive Multiple Sclerosis, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Multiple Sclerosis, Chronic Progressive with a site in Spain — 7 open to participants now, 13 under way, 8 of them phase 3. Multiple Sclerosis, Chronic Progressive · Spain.

Enrollment
25th of 28
24 · median 720
Started
2015
with 2 others
Phase 1
3 of 29
2 open now
Registered
10th of 29
by date

Among the 29 studies in Multiple Sclerosis, Chronic Progressive with a site in Spain, this one is the 25th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2015, is one of 3 in phase 1, and was the 10th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

7 of the 29 studies in Multiple Sclerosis, Chronic Progressive with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Multiple Sclerosis, Chronic Progressive with a site in Spain, or all of them as a file.
02

Study summary

Primary Objective:

  • To characterize the pharmacodynamic profile of 2 treatment courses of alemtuzumab administered by subcutaneous injection and 2 treatment courses of alemtuzumab administered by intravenous infusion in patients with progressive multiple sclerosis.

Secondary Objectives:

  • To characterize the pharmacokinetic profiles of alemtuzumab administered by subcutaneous injection or intravenous infusion to patients with progressive multiple sclerosis.
  • To characterize the safety and tolerability of alemtuzumab administered by subcutaneous injection or intravenous infusion to patients with progressive multiple sclerosis.
Read the detailed description

The duration of study per patient will be approximately 61 months.

03

Conditions studied

  • Progressive Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults with a diagnosis of Multiple Sclerosis (MS) based on 2010 revision of McDonald criteria.
  • Diagnosis of progressive MS including primary progressive MS and secondary progressive MS.
  • Age ≥18 years.
  • Signed form.
  • Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
  • Not under any administrative or legal supervision.

Exclusion criteria

Exclusion criteria:

  • Patients with relapsing remitting MS.
  • Any prior treatment with alemtuzumab or other anti-CD52 antibodies.
  • Treatment with natalizumab in the 4 months prior to Study Visit 1.
  • Progressive multifocal leukoencephalopathy (PML), or any clinical or imaging signs possibly indicative of undiagnosed PML. Particular vigilance is needed for patients with prior natalizumab exposure, even if the last exposure was more than 4 months prior to Study Visit 1.
  • Treatment with methotrexate, azathioprine, or cyclosporine in the past 6 months.
  • Treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab, or any other or cytotoxic therapy (other than ) in the last 12 months, or determined by the treating physician to have residual immune suppression from these treatments.
  • Treatment with glatiramer acetate or interferon beta in the past 4 weeks.
  • Treatment with fingolimod within the past 2 months.
  • Treatment with dimethyl fumarate in the past 4 weeks.
  • Treatment with teriflunomide within the past 12 months unless the patient has completed an accelerated clearance with cholestyramine or activated charcoal.
  • Any known to the symptomatic therapy used in the infusion management guidance for this study.
  • or contraindication to acyclovir.
  • History of a hypersensitivity reaction other than localized injection site reaction to any biological molecule.
  • If female, pregnancy (defined as positive β-HCG blood test) or lactating or breast-feeding.
  • Current participation in another interventional study.
  • Any significant change in chronic treatment medication (ie, new chronic medication) within 14 days before inclusion.
  • An investigational medicinal product within 3 months or 5 half-lives, whichever is longer, before study inclusion.
  • Total lymphocyte or CD3+ counts are below normal limits at screening. If abnormal cell count(s) return to within normal limits, eligibility may be reassessed.
  • Live, attenuated vaccine within 3 months prior to the randomization (Day 1) visit, such as varicella-zoster, oral polio, rubella vaccines.
  • Any findings in the physical examination, medical history, or laboratory assessments which would compromise the safety of the patient.
  • Women of not protected by highly-effective method(s) of and/or who are unwilling or unable to be tested for pregnancy.
  • Latent or active tuberculosis infection, verified by testing as per local practice.
  • Infection with (HIV).
  • Known (HBV) or (HCV) infection.
  • Active infection, eg, deep tissue infection, that the Investigator considers sufficiently serious to preclude study participation.
  • Prior history of invasive fungal infections.
  • Any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  • Any patient in the exclusion period of a previous study according to applicable regulations.
  • Any patient who cannot be contacted in case of emergency.
  • Any patient who is the Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    alemtuzumab (subcutaneous injection)

    Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine \[loratadine, cetirizine, dexchlorpheniramine\], paracetamol, acyclovir) will be administered prior alemtuzumab administration.

    Drug: Acyclovir · Drug: Methylprednisolone · Drug: alemtuzumab GZ402673 · Drug: Paracetamol · Drug: Loratadine · Drug: Ceterizine · Drug: Dexchlorpheniramine

  • Experimental
    alemtuzumab (intravenous infusion)

    Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine \[loratadine, cetirizine, dexchlorpheniramine\], paracetamol, acyclovir) will be administered prior alemtuzumab administration.

    Drug: Acyclovir · Drug: Methylprednisolone · Drug: alemtuzumab GZ402673 · Drug: Paracetamol · Drug: Loratadine · Drug: Ceterizine · Drug: Dexchlorpheniramine

Interventions

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:solution for infusion Route of administration: intravenous

  • Pharmaceutical form:injection Route of administration: subcutaneous

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change from baseline in the CD3+ lymphocyte subset after alemtuzumab administration

    Time frame: Baseline, 30 days after each treatment course

Secondary outcomes

  1. Change from baseline in lymphocyte subsets after alemtuzumab administration

    Time frame: Baseline, 30 days after each treatment course

  2. Change from baseline in total lymphocyte count after alemtuzumab administration

    Time frame: Baseline, 30 days after each treatment course

  3. Change from baseline in helper/suppressor ratio after alemtuzumab administration

    Time frame: Baseline, 30 days after each treatment course

  4. Assessment of pharmacokinetic parameter after alemtuzumab administration: maximum plasma concentration observed (Cmax)

    Time frame: 30 days after each treatment course

  5. Assessment of pharmacokinetic parameter after alemtuzumab administration: time to reach Cmax (Tmax)

    Time frame: 30 days after each treatment course

  6. Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration versus time curve from time zero until the last measurable concentration (AUClast)

    Time frame: 30 days after each treatment course

  7. Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration (AUC)

    Time frame: 30 days after each treatment course

  8. Assessment of pharmacokinetic parameter after alemtuzumab administration: terminal half-life (t1/2z)

    Time frame: 30 days after each treatment course

  9. Number of patients with adverse events

    Time frame: 4 years

  10. Number of patients with adverse events of special interest

    Time frame: 4 years

  11. Number of patients with injection site reactions

    Time frame: 2 years

07

Study locations

1 site
  • Investigational Site Number 724001
    Barcelona, 08035, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Mar 2016, 3 months.

Of 21 phase 1 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2015
First posted
Oct 22, 2015
StartActual
Dec 6, 2015
Primary completionActual
Mar 2016
CompletionActual
Mar 1, 2021
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02583594
Responsible party
Sponsor
First posted
Oct 22, 2015
Start date
Dec 6, 2015
Primary completion
Mar 2016
Completion
Mar 1, 2021
Last update
Mar 10, 2021

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acyclovir · Methylprednisolone · Alemtuzumab · Acetaminophen · Loratadine · Cetirizine · Dexchlorpheniramine

Start the discussion